Key Figures
The Metall Zug Group is committed to transparency, clarity and accuracy. Our key figures provide a comprehensive overview of the group's business development and our Business Units. Additional explanations of the key figures can be found in the published Annual Reports.
Sales by Business Units 2024
in CHF million
283.4
Operating Income (EBIT) 2024
in CHF million
58.0
Employees 2024
983
Net Sales with Third Parties by Region 2024
in %
Net Sales by Business Units 2024
in %
Organic Sales Development 2024
in %
-8.3
Cash Flow from Operating Activities 2024
in CHF million
2.8
Earnings per Share 2024
in CHF
116.87
Equity Ratio 2024
in %
76.8%
| Metall Zug Group | 2024 | 1) | 2023 |
| 2022 | 2) | 2021 |
| 2020 | 3) |
|---|---|---|---|---|---|---|---|---|---|---|
in CHF million |
|
|
|
| ||||||
|
|
|
| |||||||
| Performance |
|
|
|
| ||||||
| Net sales | 283.4 | 494.7 | 645.9 | 661.9 | 823.5 | |||||
| Trading operating result | 54.9 | 13.1 | 4) | 134.7 | 4) | 42.3 | 15.5 | |||
| Result from strategic investments | 3.1 | 17.0 | 10.2 | 18.8 | 6.8 | |||||
| Operating result (EBIT) | 58.0 | 30.1 | 4) | 144.9 | 4) | 61.1 | 22.3 | |||
| Net income | 52.8 | 26.1 | 4) | 136.1 | 4) | 53.3 | 13.5 | |||
| Earnings per share (EPS) | 116.87 | 48.13 | 4) | 286.25 | 4) | 108.83 | 31.93 | |||
|
|
|
|
| ||||||
| Sales development in % | -42.7 | -23.4 | -2.4 | -19.6 | -31.1 | |||||
| of which foreign currency impact in % | -0.8 | -2.5 | -0.3 | -0.1 | -1.7 | |||||
| of which acquisition & divestment impact in % | -33.6 | 5) | -25.7 | 6) | -11.6 | 6) | -30.0 | 7) | -22.6 | 7) |
| Organic sales development in % | -8.3 | 4.8 | 9.5 | 10.5 | -6.8 | |||||
|
|
|
|
| ||||||
| Cash flow from operating activities | 2.8 | 9.5 | -6.0 | 48.9 | 60.2 | |||||
| in % of net sales | 1.0 | 1.9 | -0.9 | 7.4 | 7.3 | |||||
| Employees | 983 | 2’224 | 2’317 | 3’321 | 3’090 | |||||
| Personnel expenses | -154.7 | -218.8 | -282.3 | -303.0 | -365.8 | |||||
|
|
|
|
| ||||||
| Invested Capital |
|
|
|
| ||||||
| Total assets | 633.0 | 688.9 | 4) | 700.0 | 4) | 715.6 | 635.2 | |||
|
|
|
|
| ||||||
| Net debt/net cash8) | -65.6 | -6.8 | 14.7 | 77.7 | 67.6 | |||||
| in % of total assets | -10.4 | -1.0 | 2.1 | 10.9 | 10.6 | |||||
|
|
|
|
| ||||||
| Current assets | 129.5 | 236.8 | 4) | 284.7 | 4) | 378.9 | 316.7 | |||
| in % of total assets | 20.5 | 34.4 | 40.7 | 52.9 | 49.9 | |||||
|
|
|
|
| ||||||
| Fixed assets | 503.4 | 452.1 | 415.3 | 336.8 | 318.5 | |||||
| in % of total assets | 79.5 | 65.6 | 59.3 | 47.1 | 50.1 | |||||
|
|
|
|
| ||||||
| Strategic investments (associated companies) | 295.1 | 249.0 | 244.7 | 135.8 | 117.0 | |||||
| in % of total assets | 46.6 | 36.1 | 35.0 | 19.0 | 18.4 | |||||
|
|
|
|
| ||||||
| Shareholders' equity | 486.4 | 520.0 | 4) | 517.1 | 4) | 516.2 | 482.9 | |||
| in % of total assets | 76.8 | 75.6 | 73.9 | 72.1 | 76.0 | |||||
|
|
|
|
| ||||||
| Investments in tangible and intangible assets | 33.9 | 36.2 | 34.8 | 34.7 | 46.1 | |||||
| Investments (expenses) in research and development | -33.2 | -41.0 | -54.6 | -60.4 | -75.1 | |||||
1) On June 7, 2024, the Infection Control Business Unit and the Belimed Life Science Group were deconsolidated and contributed into SteelcoBelimed AG. In return, Metall Zug AG received a 33% stake in SteelcoBelimed AG. As a consequence, the 2024 performance figures are not comparable with the other years stated. |
2) On August 30, 2022, the Schleuniger Group (Wire Processing Business Unit) was deconsolidated and contributed into Komax Holding AG. In return, Metall Zug AG received a 25% stake in Komax Holding AG. As a consequence, the 2022 performance figures are not comparable with the other years stated. |
3) The V-ZUG Group was spun-off on June 25, 2020. Accordingly, the 2020 performance figures are not comparable with the other years stated. |
4) 2023 and 2022 restated. |
5) 2024 solely in connection with the deconsolidation of the Business Unit Infection Control and the Belimed Life Science Group. |
6) Of which -24.6% related to the deconsolidation of the Schleuniger Group in 2023 (2022: -11.1%). |
7) Of which -31.7% related to the spin-off of V-ZUG Group in 2021 (2020: -23.6%) |
8) Net debt/net cash is made up of cash and cash equivalents and securities less financial liabilities. |
Net Sales 2024
in CHF million
167.6
Operating Income (EBIT) 2024
in CHF million / in % of net sales
1.1 / 0.6%
Organic Net Sales Development 2024
in %
–4.9%
Employees (FTE) 2024
781
Net Sales by Segment 2024
in %
Net Sales by Region 2024
in %
| Medical Devices | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
in CHF million | |||||
| Net sales | 167.6 | 178.3 | 225.6 | 215.2 | 169.6 |
| Net sales development in % | -6.0 | -20.9 | 4.8 | 26.9 | -17.2 |
| - of which foreign currency impact in % | -1.1 | -2.8 | -0.6 | -0.3 | -3.0 |
| - of which acquisition & divestment impact in % | 0.0 | -4.0 | -3.2 | 2.5 | 3.6 |
| Organic net sales development in % | -4.9 | -14.1 | 8.6 | 24.7 | -17.8 |
| Net sales to third parties | 167.6 | 178.3 | 225.6 | 215.2 | 169.6 |
| - Switzerland | 10.1 | 9.4 | 8.1 | 8.2 | 8.3 |
| - Europe (excluding Switzerland) | 57.0 | 60.8 | 71.7 | 79.6 | 67.6 |
| - Americas | 74.2 | 80.2 | 111.7 | 92.1 | 63.1 |
| - Asia / Pacific / Others | 26.3 | 28.0 | 34.1 | 35.3 | 30.6 |
| Investments (expenses) in research and development | -27.3 | -25.1 | -22.7 | -24.3 | -20.5 |
| Operating income (EBIT) | 1.1 | 15.2 | 28.8 | 24.6 | -4.4 |
| - in % of net sales | 0.6 | 8.5 | 12.8 | 11.4 | -2.6 |
| Operating income (EBIT) excl. research and development | 28.4 | 40.3 | 51.5 | 48.9 | 16.1 |
| - in % of net sales | 17.0 | 22.6 | 22.8 | 22.7 | 9.5 |
Other Operating Income 2024
in CHF million
13.3
Operating Income (EBIT) 2024
in CHF million
2.9
Fixed Assets & Assets Built for Sale 2024
in CHF million
144.8
Employees 2024
31
| Technologycluster & Infrastructure | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
in CHF million | |||||
| Other operating income | 13.3 | 12.6 | 12.7 | 12.0 | 15.8 |
| Operating income (EBIT) | 2.9 | 5.2 | 2.9 | 2.5 | 5.2 |
| Fixed assets & assets built for sale | 144.8 | 122.9 | 127.4 | 106.4 | 83.3 |
Net Sales 2024
in CHF million
49.1
Trading operating result 2024
in CHF million / in % from net sales
54.8 / 111.7%
Result from strategic investments 2024
in CHF million
3.1
Operating income (EBIT) 2024
in CHF million
57.9
Organic net sales development 2024
in %
-11.9%
Employees (FTE) 2024
170
| Investments & Corporate | 2024 | 1) | 2023 | 2022 | 2) | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
in CHF million | |||||||
| Net sales | 49.1 | 117.3 | 86.2 | 68.4 | 75.6 | ||
| Net sales development in % | -58.1 | 36.1 | 26.1 | -9.5 | -0.6 | ||
| - of which foreign currency impact in % | -0.1 | -1.3 | 0.5 | 0.0 | -0.3 | ||
| - of which acquisition impact in % | -46.1 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| Organic net sales development in % | -11.9 | 37.4 | 25.6 | -9.5 | -0.3 | ||
| Net sales to third parties | 48.4 | 115.5 | 84.1 | 67.7 | 74.5 | ||
| - Switzerland | 36.2 | 45.3 | 41.4 | 32.5 | 32.9 | ||
| - Europe (excluding Switzerland) | 8.4 | 45.3 | 25.5 | 18.3 | 18.8 | ||
| - Americas | 3.3 | 18.4 | 8.4 | 12.8 | 19.7 | ||
| - Asia / Pacific / Others | 0.6 | 6.6 | 8.8 | 4.1 | 3.1 | ||
| Trading operating result | 54.8 | 3) | -4.0 | 82.6 | 4) | -2.1 | -1.1 |
| - in % of net sales | 111.7 | -3.4 | 95.8 | -3.0 | -1.4 | ||
| Result from strategic investments (associated companies) | 3.1 | 17.0 | 9.9 | 18.9 | 7.0 | ||
| Operating income (EBIT) | 57.9 | 3) | 13.0 | 92.5 | 4) | 16.9 | 5.9 |
1) Contains the pro rata results of the Belimed Life Science Group up to June 7, 2024. |
2) As of Janaury 1, 2022, Belimed Life Science, which is included in the Others reporting segment, took over the service business for Life Science customers from the Infection Control Business Unit. This impact is included in the organic net sales development. The 2021 sales for this service business amounted to CHF 12.0 million (17.5% of the 2021 sales). |
3) Includes the gain of CHF 66.6 million related to the deconsolidation of the Infection Control Business Unit and the Belimed Life Science Group and their contribution into the newly founded joint venture SteelcoBelimed AG in exchange for a minority stake of 33 % in SteelcoBelimed AG. |
4) Includes the gain of CHF 89.7 million from the contribution of the Schleuniger Group into the Komax Group in exchange for a minority stake of 25% in Komax Holding AG. |